{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:20:44Z","timestamp":1773080444994,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epstein\u2013Barr virus (EBV) infection is well-known for its high prevalence rate, association with several diseases including cancer and autoimmune conditions, and a wide variety of symptoms and prognosis. When acquired at a young age, primary infections are often asymptomatic; however, in adolescence and young adulthood, symptomatic infections develop, such as in infectious mononucleosis. A special feature of EBV infection is its ability to establish a latent infection in B cells which can lead to long-term infection. Subsequent cellular transformation and viral protein expression can result to EBV-mediated carcinogenesis. Latent proteins expressed by EBV play a role in the pathogenesis of EBV infection and carcinogenesis. These proteins are responsible for a diverse range of functions including cell transformation, cell reprogramming, immune evasion, immune suppression, angiogenesis, cell cycle regulation, and B-cell receptor mimicry.<\/jats:p>\n                  <jats:p>EBV infection is associated with diffuse large B-cell lymphoma, Hodgkin lymphoma, NK\/T cell lymphoma, Burkitt lymphoma, post-transplant lymphoproliferative disorders, and primary CNS lymphoma. The clinical presentation varies depending on the specific disease and EBV status, with EBV-positive lymphomas generally associated with poorer prognosis than EBV-negative cases.<\/jats:p>\n                  <jats:p>This review aimed to examine the current understanding of the pathogenesis of EBV-associated lymphoma and to evaluate emerging and accepted therapeutic strategies.<\/jats:p>","DOI":"10.1007\/s44313-026-00127-4","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T06:16:26Z","timestamp":1772864186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epstein\u2013Barr virus-associated lymphoma: current understanding and treatment strategies"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6744-0412","authenticated-orcid":false,"given":"Hee Young","family":"Ju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"20","key":"127_CR1","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: biology and clinical disease. Cell. 2022;185(20):3652\u201370.","journal-title":"Cell"},{"issue":"7335","key":"127_CR2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma. Lancet. 1964;1(7335):702\u20133.","journal-title":"Lancet"},{"issue":"5","key":"127_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1084\/jem.121.5.761","volume":"121","author":"MA Epstein","year":"1965","unstructured":"Epstein MA, Henle G, Achong BG, Barr YM. Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt\u2019s lymphoma. J Exp Med. 1965;121(5):761\u201370.","journal-title":"J Exp Med"},{"issue":"13","key":"127_CR4","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMra032015","volume":"350","author":"DA Thorley-Lawson","year":"2004","unstructured":"Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350(13):1328\u201337.","journal-title":"N Engl J Med"},{"key":"127_CR5","first-page":"355","volume":"391","author":"ME Ressing","year":"2015","unstructured":"Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ. Immune evasion by Epstein-Barr virus. Curr Top Microbiol Immunol. 2015;391:355\u201381.","journal-title":"Curr Top Microbiol Immunol"},{"key":"127_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coviro.2021.11.013","volume":"52","author":"R Guo","year":"2022","unstructured":"Guo R, Gewurz BE. Epigenetic control of the Epstein-Barr lifecycle. Curr Opin Virol. 2022;52:78\u201388.","journal-title":"Curr Opin Virol"},{"issue":"10","key":"127_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41579-025-01181-y","volume":"23","author":"C Munz","year":"2025","unstructured":"Munz C. Epstein-Barr virus pathogenesis and emerging control strategies. Nat Rev Microbiol. 2025;23(10):667\u201379.","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"127_CR8","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"C de Martel","year":"2020","unstructured":"de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180\u201390.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"127_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","volume":"148","author":"Y Wong","year":"2022","unstructured":"Wong Y, Meehan MT, Burrows SR, Doolan DL, Miles JJ. Estimating the global burden of Epstein-Barr virus-related cancers. J Cancer Res Clin Oncol. 2022;148(1):31\u201346.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"127_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cell.2015.07.019","volume":"162","author":"DF Robbiani","year":"2015","unstructured":"Robbiani DF, Deroubaix S, Feldhahn N, Oliveira TY, Callen E, Wang Q, et al. Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma. Cell. 2015;162(4):727\u201337.","journal-title":"Cell"},{"issue":"7","key":"127_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/ijc.24014","volume":"124","author":"AM Moormann","year":"2009","unstructured":"Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R, Otieno JA, et al. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer. 2009;124(7):1721\u20136.","journal-title":"Int J Cancer"},{"issue":"8","key":"127_CR12","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1086\/428910","volume":"191","author":"AM Moormann","year":"2005","unstructured":"Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder R, Newton D, et al. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis. 2005;191(8):1233\u20138.","journal-title":"J Infect Dis"},{"key":"127_CR13","doi-asserted-by":"crossref","unstructured":"McHugh D, Myburgh R, Caduff N, Spohn M, Kok YL, Keller CW, et al. EBV renders B cells susceptible to HIV-1 in humanized mice. Life Sci Alliance.\u00a02020;3(8):e202000640.","DOI":"10.26508\/lsa.202000640"},{"key":"127_CR14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fonc.2019.00713","volume":"9","author":"C Shannon-Lowe","year":"2019","unstructured":"Shannon-Lowe C, Rickinson A. The global landscape of EBV-associated tumors. Front Oncol. 2019;9:713.","journal-title":"Front Oncol"},{"key":"127_CR15","doi-asserted-by":"crossref","unstructured":"Sausen DG, Basith A, Muqeemuddin S. EBV and Lymphomagenesis. Cancers (Basel). 2023;15(7).","DOI":"10.3390\/cancers15072133"},{"key":"127_CR16","doi-asserted-by":"crossref","unstructured":"Chiu YF, Ponlachantra K, Sugden B. How Epstein Barr Virus Causes Lymphomas. Viruses. 2024;16(11).","DOI":"10.3390\/v16111744"},{"issue":"2","key":"127_CR17","doi-asserted-by":"publisher","first-page":"e70192","DOI":"10.1002\/jmv.70192","volume":"97","author":"J Jiang","year":"2025","unstructured":"Jiang J, Zhu X, Li S, Yan Q, Ma J. Building a bridge between the mechanism of EBV reactivation and the treatment of EBV-associated cancers. J Med Virol. 2025;97(2):e70192.","journal-title":"J Med Virol"},{"issue":"1","key":"127_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.pathol.2019.09.006","volume":"52","author":"ML Marques-Piubelli","year":"2020","unstructured":"Marques-Piubelli ML, Salas YI, Pachas C, Becker-Hecker R, Vega F, Miranda RN. Epstein-barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review. Pathology. 2020;52(1):40\u201352.","journal-title":"Pathology"},{"issue":"10","key":"127_CR19","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/onc.2013.71","volume":"33","author":"DT Vereide","year":"2014","unstructured":"Vereide DT, Seto E, Chiu YF, Hayes M, Tagawa T, Grundhoff A, et al. Epstein-barr virus maintains lymphomas via its miRNAs. Oncogene. 2014;33(10):1258\u201364.","journal-title":"Oncogene"},{"issue":"4","key":"127_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5483\/BMBRep.2016.49.4.260","volume":"49","author":"KW Noh","year":"2016","unstructured":"Noh KW, Park J, Kang MS. Targeted disruption of EBNA1 in EBV-infected cells attenuated cell growth. BMB Rep. 2016;49(4):226\u201331.","journal-title":"BMB Rep"},{"issue":"3","key":"127_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","volume":"27","author":"X Wang","year":"2015","unstructured":"Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015;27(3):443\u201352.","journal-title":"Cell Signal"},{"issue":"20","key":"127_CR22","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/blood-2017-10-810630","volume":"131","author":"A Stelling","year":"2018","unstructured":"Stelling A, Hashwah H, Bertram K, Manz MG, Tzankov A, Muller A. The tumor suppressive TGF-beta\/SMAD1\/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. Blood. 2018;131(20):2235\u201346.","journal-title":"Blood"},{"issue":"5","key":"127_CR23","doi-asserted-by":"publisher","first-page":"e0216898","DOI":"10.1371\/journal.pone.0216898","volume":"14","author":"S Nagel","year":"2019","unstructured":"Nagel S, Uphoff CC, Dirks WG, Pommerenke C, Meyer C, Drexler HG. Epstein-barr virus (EBV) activates NKL homeobox gene HLX in DLBCL. PLoS ONE. 2019;14(5):e0216898.","journal-title":"PLoS ONE"},{"issue":"7","key":"127_CR24","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/modpathol.2012.52","volume":"25","author":"S Montes-Moreno","year":"2012","unstructured":"Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosia SG, Mazorra F, et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol. 2012;25(7):968\u201382.","journal-title":"Mod Pathol"},{"issue":"1","key":"127_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/path.2384","volume":"216","author":"M Vockerodt","year":"2008","unstructured":"Vockerodt M, Morgan SL, Kuo M, Wei W, Chukwuma MB, Arrand JR, et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin\u2019s Reed-Sternberg-like phenotype. J Pathol. 2008;216(1):83\u201392.","journal-title":"J Pathol"},{"issue":"11","key":"127_CR26","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1080\/10428194.2019.1607330","volume":"60","author":"SP Aravinth","year":"2019","unstructured":"Aravinth SP, Rajendran S, Li Y, Wu M, Yi Wong AH, Schwarz H. Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway. Leuk Lymphoma. 2019;60(11):2697\u2013704.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"127_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/jmv.25381","volume":"91","author":"R Incrocci","year":"2019","unstructured":"Incrocci R, McAloon J, Montesano M, Bardahl J, Vagvala S, Stone A, et al. Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-kappaB in B-cell lymphomas to increase MIP-1alpha production. J Med Virol. 2019;91(5):845\u201355.","journal-title":"J Med Virol"},{"issue":"12","key":"127_CR28","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1038\/s41379-020-0575-3","volume":"33","author":"L Mundo","year":"2020","unstructured":"Mundo L, Del Porro L, Granai M, Siciliano MC, Mancini V, Santi R, et al. Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas. Mod Pathol. 2020;33(12):2407\u201321.","journal-title":"Mod Pathol"},{"key":"127_CR29","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720\u201348.","DOI":"10.1038\/s41375-022-01620-2"},{"issue":"12","key":"127_CR30","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835\u201349.","journal-title":"J Clin Oncol"},{"issue":"12","key":"127_CR31","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","volume":"133","author":"BM Grande","year":"2019","unstructured":"Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133(12):1313\u201324.","journal-title":"Blood"},{"issue":"19","key":"127_CR32","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/blood.2019001880","volume":"134","author":"RI Panea","year":"2019","unstructured":"Panea RI, Love CL, Shingleton JR, Reddy A, Bailey JA, Moormann AM, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134(19):1598\u2013607.","journal-title":"Blood"},{"issue":"4","key":"127_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/MOH.0000000000000059","volume":"21","author":"A Greenough","year":"2014","unstructured":"Greenough A, Dave SS. New clues to the molecular pathogenesis of Burkitt lymphoma revealed through next-generation sequencing. Curr Opin Hematol. 2014;21(4):326\u201332.","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"127_CR34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood.2019000568","volume":"134","author":"PG Murray","year":"2019","unstructured":"Murray PG, Young LS. An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. Blood. 2019;134(7):591\u20136.","journal-title":"Blood"},{"issue":"1","key":"127_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1600-0463.2010.02685.x","volume":"119","author":"M Spacek","year":"2011","unstructured":"Spacek M, Hubacek P, Markova J, Zajac M, Vernerova Z, Kamaradova K, et al. Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients. APMIS. 2011;119(1):10\u20136.","journal-title":"APMIS"},{"issue":"18","key":"127_CR36","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1182\/blood-2012-09-454694","volume":"121","author":"JA Kanakry","year":"2013","unstructured":"Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood. 2013;121(18):3547\u201353.","journal-title":"Blood"},{"issue":"2","key":"127_CR37","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1016\/S2352-3026(15)00002-2","volume":"2","author":"SJ Kim","year":"2015","unstructured":"Kim SJ, Choi JY, Hyun SH, Ki CS, Oh D, Ahn YC, et al. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer\/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematol. 2015;2(2):e66-74.","journal-title":"Lancet Haematol"},{"issue":"6","key":"127_CR38","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","volume":"109","author":"SP Perrine","year":"2007","unstructured":"Perrine SP, Hermine O, Small T, Suarez F, O\u2019Reilly R, Boulad F, et al. A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109(6):2571\u20138.","journal-title":"Blood"},{"issue":"10","key":"127_CR39","doi-asserted-by":"publisher","first-page":"e1012341","DOI":"10.1371\/journal.ppat.1012341","volume":"20","author":"ED SoRelle","year":"2024","unstructured":"SoRelle ED, Haynes LE, Willard KA, Chang B, Ch\u2019ng J, Christofk H, et al. Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression. PLoS Pathog. 2024;20(10):e1012341.","journal-title":"PLoS Pathog"},{"issue":"14","key":"127_CR40","doi-asserted-by":"publisher","first-page":"12603","DOI":"10.18632\/oncotarget.3687","volume":"6","author":"M Lee","year":"2015","unstructured":"Lee M, Son M, Ryu E, Shin YS, Kim JG, Kang BW, et al. Quercetin-induced apoptosis prevents EBV infection. Oncotarget. 2015;6(14):12603\u201324.","journal-title":"Oncotarget"},{"key":"127_CR41","doi-asserted-by":"crossref","unstructured":"Guo R, Jiang C, Zhang Y, Govande A, Trudeau SJ, Chen F, et al. MYC Controls the Epstein-Barr Virus Lytic Switch. Mol Cell. 2020;78(4):653\u201369 e8.","DOI":"10.1016\/j.molcel.2020.03.025"},{"issue":"21","key":"127_CR42","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood.2019004126","volume":"135","author":"T Dalton","year":"2020","unstructured":"Dalton T, Doubrovina E, Pankov D, Reynolds R, Scholze H, Selvakumar A, et al. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Blood. 2020;135(21):1870\u201381.","journal-title":"Blood"},{"issue":"20","key":"127_CR43","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1182\/bloodadvances.2023010330","volume":"7","author":"B Haverkos","year":"2023","unstructured":"Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, et al. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b\/2 study. Blood Adv. 2023;7(20):6339\u201350.","journal-title":"Blood Adv"},{"issue":"2","key":"127_CR44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bjh.19255","volume":"204","author":"K Bednarska","year":"2024","unstructured":"Bednarska K, Chowdhury R, Tobin JWD, Swain F, Keane C, Boyle S, et al. Epstein-Barr virus-associated lymphomas decoded. Br J Haematol. 2024;204(2):415\u201333.","journal-title":"Br J Haematol"},{"issue":"1","key":"127_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s44313-024-00042-6","volume":"59","author":"Y Li","year":"2024","unstructured":"Li Y, Wu Y, Cao S, Yu B, Zhang Q, Xia Z, et al. PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis. Blood Res. 2024;59(1):36.","journal-title":"Blood Res"},{"issue":"10","key":"127_CR46","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00277-021-04558-0","volume":"100","author":"WS Kim","year":"2021","unstructured":"Kim WS, Oki Y, Kim SJ, Yoon SE, Ardeshna KM, Lin Y, et al. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK\/T lymphoma: results of a multicenter study. Ann Hematol. 2021;100(10):2529\u201339.","journal-title":"Ann Hematol"},{"issue":"3","key":"127_CR47","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","volume":"25","author":"KM Mahadeo","year":"2024","unstructured":"Mahadeo KM, Baiocchi R, Beitinjaneh A, Chaganti S, Choquet S, Dierickx D, et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. Lancet Oncol. 2024;25(3):376\u201387.","journal-title":"Lancet Oncol"},{"key":"127_CR48","doi-asserted-by":"crossref","unstructured":"Bu W, Kumar A, Board NL, Kim J, Dowdell K, Zhang S, et al. Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells. Immunity. 2024;57(3):559\u201373 e6.","DOI":"10.1016\/j.immuni.2024.02.008"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00127-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00127-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00127-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:02:10Z","timestamp":1773054130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00127-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["127"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00127-4","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}